Business Wire

Federal Life Insurance Company Selects DXC Technology to Enhance Policy Buying Experience for Customers and Agents

28.4.2020 16:00:00 EEST | Business Wire | Press release

Share

Federal Life Insurance Company, based in Riverwoods, IL just northwest of Chicago, has gone live with DXC Assure for Life and Wealth to enhance the policy buying experience for their customers and agents, streamline key processes, and drive business growth. DXC’s solution is built on a scalable, cloud-based architecture, implemented on Amazon Web Services (AWS), and provided to Federal Life on an “as-a-Service” basis.

DXC Technology’s end-to-end insurance management solution streamlines new business acquisition for Federal Life by guiding producers through the data-gathering process, ensuring that all necessary information is collected at the point of sale. Information is automatically captured and submitted through a paperless, self-service process for immediate consideration. Additionally, Federal Life now benefits from straight-through processing of online policy requests with electronic signatures (e-signatures).

“Accelerating the application process and providing a superior customer experience that meets ― and exceeds ― our customers’ expectations is of critical importance to Federal Life Insurance Company,” said Bill Austin, CEO, Federal Life Group, Inc. “DXC’s platform, backed by DXC’s strong life and annuities expertise, will support us in providing a rich, easy-to-use online application experience on any device, and give us the flexibility to adapt to evolving customer needs quickly and cost effectively.”

DXC Assure for Life and Wealth encompasses electronic applications, forms management, policy administration, flexible product configuration, claims management and more. It helps insurers transform and reimagine customer-facing applications to deliver a high-quality user experience accessible on any device.

Federal Life, a longtime DXC customer, has plans to bring current and future products to DXC Assure for Life and Wealth deployed on AWS, leveraging it as a foundation to modernize the legacy IT landscape with new digital cloud-based capabilities.

“We are proud to continue our collaboration with Federal Life as it builds its digital business,” said Phil Ratcliff, vice president and general manager, Global Insurance, DXC Technology. “DXC Assure for Life and Wealth addresses key challenges that insurers are facing in today’s fast-changing market, and it will enable Federal Life to transform its business processes while improving new business speed-to-issue by streamlining and accelerating policy submission.”

DXC’s electronic application capability is a key component of DXC Assure for Life and Wealth. The overall solution accommodates contemporary life and wealth products, including term, traditional, variable and equity index life and annuity products. Business-focused API services dramatically simplify integration with customer, agent, third-party services and corporate systems. DXC Assure for Life and Wealth is an integrated solution that can be deployed in whole or in parts, enabling carriers to get into production quickly with only the components they need now.

DXC has served the global insurance industry for over 40 years, with more than 1,900 clients, active client communities and millions of policies administered on DXC’s life and annuity software and in business process services and solutions operations.

For more information on DXC Assure for Life and Wealth, click here.

About Federal Life Group, Inc.

Federal Life Group, Inc. (OTCMKTS: FLFG) is the parent of Federal Life Insurance Company (FLIC), an independently operated provider of quality life insurance and annuity products, incorporated in 1899. FLIC is headquartered in Riverwoods, Illinois, a suburb approximately thirty miles north of Chicago. FLIC is proud of its longstanding tradition of financial strength and stability. For more information, go to www.federallife.com.

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dana Greenstein, Corporate Media Relations, +1.914.607.7631, dgreenstein@dxc.com
Shailesh Murali, M&A and Investor Relations, +1.703.245.9700, shailesh.murali@dxc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level

Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release

Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye